Analysts Set ProKidney Corp. (NASDAQ:PROK) Price Target at $6.25

ProKidney Corp. (NASDAQ:PROK) has earned an average recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.25.

A number of brokerages recently commented on PROK. Wall Street Zen upgraded ProKidney from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Citigroup reiterated a “buy” rating and set a $9.00 price objective (up previously from $6.00) on shares of ProKidney in a research report on Wednesday, July 9th. UBS Group lifted their price objective on ProKidney from $4.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, July 15th. Bank of America downgraded ProKidney from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $3.00 to $1.00 in a research report on Monday, June 30th. Finally, Guggenheim reaffirmed a “buy” rating and set a $7.00 target price (up from $6.00) on shares of ProKidney in a research note on Monday, July 14th.

Insider Buying and Selling

In other ProKidney news, insider Darin J. Weber sold 103,480 shares of ProKidney stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $3.02, for a total transaction of $312,509.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 41.49% of the stock is owned by company insiders.

Hedge Funds Weigh In On ProKidney

A number of institutional investors have recently bought and sold shares of PROK. Sei Investments Co. purchased a new position in ProKidney during the fourth quarter worth about $69,000. JPMorgan Chase & Co. increased its position in shares of ProKidney by 41.8% during the fourth quarter. JPMorgan Chase & Co. now owns 66,415 shares of the company’s stock valued at $112,000 after acquiring an additional 19,585 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ProKidney by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 2,231,930 shares of the company’s stock valued at $3,773,000 after acquiring an additional 27,996 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of ProKidney by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 54,098 shares of the company’s stock valued at $91,000 after acquiring an additional 18,431 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of ProKidney by 127.7% during the fourth quarter. Renaissance Technologies LLC now owns 105,200 shares of the company’s stock valued at $178,000 after acquiring an additional 59,000 shares during the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.

ProKidney Trading Down 12.7%

PROK opened at $2.26 on Friday. The firm has a market capitalization of $661.50 million, a PE ratio of -3.77 and a beta of 1.76. ProKidney has a twelve month low of $0.46 and a twelve month high of $7.13. The firm’s 50-day moving average price is $2.02 and its 200 day moving average price is $1.37.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter. As a group, analysts predict that ProKidney will post -0.57 earnings per share for the current fiscal year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.